Equity analysts tracking Medtronic plc (NYSE: MDT) project a generally positive outlook, establishing a consensus 12-month median price target hovering around $100 to $101 per share. Wall Street ratings lean heavily toward a consensus buy recommendation, supported by steady revenue expansion in medical technology devices, robust free cash flow generation, and strong operating margins within the healthcare sector.